By increasing feelings of fullness and reducing hunger, GLP-1 medications can lead to substantial weight reduction, especially when combined with the customized dietary guidance and lifestyle support we provide
The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
Van Der Meel, M.H.A.M
The agency describes fundamental failures to ensure protocols were followed, data were accurate, and GLP regulations were met
Intergenerational Trauma and Cultural Environments Stellate ganglion blocks (SGBs) function by dampening the sympathetic nervous system, which allows the parasympathetic vagus system to express itself when an individual is locked in a state of fight or flight 2m35s
Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Development and Function